Cosmo Pharmaceuticals NV has appointed Svetlana Sigalova as chief financial officer, effective 11 November, succeeding the current CFO Niall Donnelly, who has been appointed EVP – Corporate Governance & Chief Sustainability Officer and remains a board member. Ms Sigalova was most recently vice president of commercial finance at Moderna, developing financial infrastructure and planning systems which supported Moderna’s rapid growth during the Covid pandemic. She previously held senior finance positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals. Ms Sigalova has a BSc in business administration from Babson College and an MBA in finance from Babson F.W. Olin Graduate School of Business, both US. Cosmo’s current drivers for growth include an endoscopy system that enhances polyp detection rates during colonoscopy and a treatment for acne.
